Brian Van Tine, MD, PhD, assistant professor, Washington University School of Medicine, discusses the development of olaratumab (Lartruvo) in soft tissue sarcoma.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More